• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Emory Researchers to Use Wearable ECG Patch to Predict Coronary Artery Disease

by Fred Pennic 08/30/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Emory Researchers to Use Wearable ECG Patch to Predict Coronary Artery Disease

·  New Emory University study is using VivaLNK’s medical wearable ECG sensors to evaluate autonomic function in predicting coronary artery disease (CAD).

·  VivaLNK’s ambulatory ECG patch will study patients undergoing coronary angiography in order to measure autonomic function.

·  The research goal is to better understand the role of the autonomic nervous system in depression and coronary artery disease, and to develop better tools for clinical assessment.

An Emory University study is using VivaLNK’s medical wearable ECG sensors to evaluate autonomic function in predicting coronary artery disease (CAD), as well as its relationship to mental depression and long-term outcomes. The study builds upon previous work by Emory researchers titled Circadian Autonomic Inflexibility: A Marker of Ischemic Heart Disease, which associates lower heart rate variability (HRV) with subclinical myocardial ischemia.

Study Protocol

During the study, the wearable, VivaLNK’s ECG patch, will be used to remotely monitor patients who are undergoing coronary angiography for continuous 72-hour periods in clinical and ambulatory environments. The research goal is to better understand the role of the autonomic nervous system in depression and coronary artery disease, and to develop better tools for clinical assessment. 

VivaLNK’s Medical Wearable ECG Patch

 

The VivaLNK medical wearable ECG patch contains an electrocardiography sensor and accelerometer to capture and generate multiple physiological data including ECG trace, heart rate, RR-interval, and 3-axis motion. About the size of a small bandage, the reusable and rechargeable patch weighs a mere 7.5 grams, and can be worn continuously for 72 hours at-a-time to capture and transmit data in real-time.

 

The Bigger Picture

 

Benefits of using VivaLNK’s ECG patch includes its accuracy, continuous monitoring over several days straight, and its ability to be utilized in numerous environments, connecting directly to a data platform. 

 

“VivaLNK’s ECG patch is very small and comfortable to wear, which are important factors for clinical use and long-term ECG monitoring” said Amit Shah, MD, Assistant Professor of Epidemiology at the Rollins School of Public Health at Emory University. “In addition, the software development kit makes it easy to use the patch for research and product development purposes.”

 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Depression, ecg, Emory Healthcare, Heart, heart disease, MD, Public Health, sensors, Software Development Kit

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |